Ursula Mager

TL;DR: Current evidence does not warrant recommending a particular second-generation antidepressant on the basis of differences in efficacy, but differences in onset of action and adverse events may be considered when choosing a medication.

TL;DR: In this paper, the benefits and harms of bupropion, citalopram, desvenlafaxine, duloxetine, escitaloprams, fluoxetines, fluvoxamine, mirtazapine, nefazodone, paroxetinedine, sertraline, trazodone and venlaxine were compared for the treatment of depressive disorders.

TL;DR: In this article, the benefits and harms of second-generation antidepressants for treating major depressive disorder in adults were compared on the basis of 234 studies, and no clinically relevant differences in the two groups were found.

TL;DR: Evidence guiding the selection of an SGA based on accompanying symptoms of depression is limited, and where evidence is available, it suggests no difference between SGAs in their efficacy for treating the depressive episode or the accompanying symptom.